Business
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
HIBRUKA (Orelabrutinib) Approval of HIBRUKA (Orelabrutinib) for the Treatment of R/R MZL in Singapore BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL). Dr. Jasmine Cui,
About this update from Innocare Pharma Ltd. Class A
[{"type":"image","alt":"InnoCare Pharma","displaySize":"","headline":null,"caption":"InnoCare Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_HX0Yb8ZoWwOiU8iDHIydw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1885e93031454229063957b3a9d6b6ec","width":300,"height":116}},"lazy":false},{"type":"text","content":"HIBRUKA (Orelabrutinib)","length":23,"tagName":"p"},{"type":"image","alt":"Approval of HIBRUKA (Orelabrutinib) for the Treatment of R/R MZL in Singapore","displaySize":"","headline":null,"caption":"Approval of HIBRUKA (Orelabrutinib) for the Treatment of R/R MZL in Singapore","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/globenewswire.com/6ba53841005791814f97171ba1307a7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VIzi8JM4VkuxHz.efPMujg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6ba53841005791814f97171ba1307a7d","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NwnvIZ4sulB71DUNgpjg_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/6ba53841005791814f97171ba1307a7d","width":1200,"height":675}}},{"type":"text","content":"BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL).","length":380,"tagName":"p"},{"type":"text","content":"Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said, “We are excited to obtain a second indication approval in Singapore. As a highly selective BTK inhibitor, orelabrutinib has demonstrated good efficacy and safety in the treatment of R/R MZL. The approval in Singapore will offer a new treatment option to local lymphoma patients. In addition to lymphoma, we are advancing global clinical trials for orelabrutinib in a...